Search Results
Your search for The ASCO Post matches 17400 pages
Showing 12701 - 12750ASCO 2016: New Antibody-Drug Conjugate Shows Early Promise in Small Cell Lung Cancer
Early findings from a first-in-human clinical trial showed that the antibody-drug conjugate rovalpituzumab tesirine (Rova-T) shows promising efficacy against recurrent small cell lung cancer (SCLC). The treatment, which combines a novel anti-DLL3 antibody with a powerful anticancer agent, halted...
ASCO 2016: Temozolomide Chemotherapy Plus Short-Course Radiotherapy Improves Survival in Elderly Patients With Glioblastoma
A Canadian-led randomized phase III trial found that adding temozolomide chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide, significantly improved survival of elderly patients with glioblastoma, reducing the risk of death by 33%. These data...
ASCO 2016: 10 Years of Aromatase Inhibitor Therapy Reduces Breast Cancer Recurrence Without Compromising Quality of Life in Postmenopausal Patients
For updated findings on aromatase inhibitor therapy from the 2016 San Antonio Breast Cancer Symposium, please click here, here, or here. A randomized phase III clinical trial, MA.17R, found that postmenopausal women with early breast cancer benefit from extending aromatase inhibitor therapy with...
Usha Menon, MD, on Ovarian Cancer: Advances in Early Detection
Usha Menon, MD, of University College London, discusses a significant new version of a screening test for ovarian cancer that may reduce death from the disease (Abstract 5507).
Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial (Italian Language Version) 
Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses in Italian results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). To see the English language ...
Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial
Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). To see the Italian version of this...
Maria Clemence Schwaederle, PharmD, on Precision Medicine: Its Impact in Refractory Malignancies
Maria Clemence Schwaederle, PharmD, of the University of California, San Diego, discusses an analysis of 13,203 patients in phase I clinical trials, which showed that a personalized strategy led to improved response rate and progression-free survival (Abstract 11520).
Lawrence N. Shulman, MD, and Daniel A. Goldstein, MD: Expert Perspectives on Issues in Global Cancer Care
Lawrence N. Shulman, MD, of Abramson Cancer Center at the University of Pennsylvania, and Daniel A. Goldstein, MD, of the Rabin Medical Center, discuss global challenges in cancer care, including treating patients in areas lacking resources, and cancer drug price disparities (Abstract LBA6500).
Ghassan K. Abou-Alfa, MD, on Sorafenib and Doxorubicin for Advanced Hepatocellular Carcinoma
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses findings of this phase III study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (Abstract 4003).
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the SQUIRE Trial
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. To see Dr. Paz-Ares discuss this video in...
ASCO 2016: Rucaparib Shows Clinical Benefit in BRCA-Mutated Pancreatic Cancer
The targeted PARP inhibitor rucaparib, which has demonstrated robust clinical activity in patients with ovarian cancer who have a BRCA mutation, also showed promise in previously treated patients with pancreatic cancer who have the mutation, according to results from a phase II clinical study...
Nikhil Wagle, MD, on The Metastatic Breast Cancer Project: Progress Report
Nikhil Wagle, MD, of the Dana-Farber Cancer Institute, discusses the strides made in this national direct-to-patient initiative to accelerate genomics research (Abstract LBA1519).
ASCO 2016: Maintenance Lenalidomide After Autologous Stem Cell Transplantation Improves Survival in Multiple Myeloma
Several clinical trials have demonstrated that maintenance therapy with lenalidomide (Revlimid) after autologous hematopoietic stem cell transplant reduces the risk of disease progression in patients with multiple myeloma, but there have been no definitive results regarding overall...
John D. Hainsworth, MD, on Advanced Solid Tumors: Results From the MyPathway Trial
John D. Hainsworth, MD, of the Sarah Cannon Research Institute, discusses early findings from this umbrella basket study on targeted treatment, outside of current drug indications, for different types of advanced solid tumors (Abstract LBA11511).
Lee S. Schwartzberg, MD, on Progress of the Institute for Clinical Immuno-Oncology
Lee S. Schwartzberg, MD, of The West Clinic, reports on progress of the now year-old ACCC initiative to speed adoption of immunotherapeutics in community practices.
ASCO 2016: Locoregional Surgery Followed by Standard Therapy Improves Survival vs Standard Therapy Alone in Stage IV Breast Cancer
Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer followed by standard combination therapies improved survival over standard therapy alone, an international clinical trial revealed. The results of the phase III randomized, controlled trial were presented today...
ASCO 2016: Nivolumab Alone or in Combination With Ipilimumab Active in Recurrent Small Cell Lung Cancer
A study presented by Antonia et al at the 2016 ASCO Annual Meeting (Abstract 100) showed that utilizing the immunotherapeutic agents nivolumab (Opdivo) and ipilimumab (Yervoy) could lead to more effective treatment options for patients with small cell lung cancer (SCLC) who have progressed after...
Yousuf Zafar, MD, on the Financial Burden of Cancer Care
Yousuf Zafar, MD, of Duke Cancer Institute, summarizes his educational lecture on the financial toxicities of treatment and the need to focus on both short- and long-term interventions to reduce the burden on patients.
Martin J. Van Den Bent, MD, PhD, on Anaplastic Glioma: Results from the CATNON Trial
Martin J. Van Den Bent, MD, PhD, of the Daniel den Hoed Cancer Center, discusses the interim analysis of the EORTC phase III study on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion (Abstract LBA2000).
John P. Neoptolemos, MD, PhD, on Pancreatic Ductal Adenocarcinoma: Results of the ESPAC-4 Trial
John P. Neoptolemos, MD, PhD, of the University of Liverpool, discusses findings from this international phase III study of adjuvant combination chemotherapy: gemcitabine and capecitabine vs monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma (Abstract LBA4006).
Hope S. Rugo, MD, on HER2+ Breast Cancer: Findings on a Trastuzumab Biosimilar
Hope S. Rugo, MD, of the University of California, San Francisco, discusses phase III study results on a new possible alternative to trastuzumab for HER2-positive metastatic breast cancer: the biosimilar known as Myl-1401O (Abstract LBA503).
ASCO 2016: Innovative Direct-to-Patient Outreach May Accelerate Breast Cancer Research
An innovative project launched in October 2015 may help expedite metastatic breast cancer genomics research and provide leads for development of new treatments. In the 7 months since the launch, more than 2,000 patients have enrolled in the research study designed to collect and...
Helen MacKay, MD, on Epithelial Ovarian Cancer: Results From the OV21/PETROC Trial
Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, discusses findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in patients with epithelial ovarian cancer (Abstract LBA5503).
ASCO 2016: Liquid Biopsy May Help Guide Treatment Decisions for Patients With Advanced Solid Tumors
A large-scale genomic analysis found that patterns of genetic changes detected in blood samples (liquid biopsy) closely mirror those identified in traditional tumor biopsy. With blood samples from more than 15,000 patients and 50 different tumor types, this is one of the largest cancer genomics...
ASCO 2016: Precision Medicine Approach May Expand Therapeutic Options for Patients
Researchers reported encouraging early results from a phase II trial that matches patients with molecular abnormalities in the tumor to corresponding targeted treatments. Twenty-nine of 129 patients with 12 different types of advanced cancers responded to drugs outside of U.S. Food and Drug...
ASCO 2016: Chemotherapy Improves Outcomes for Certain Patients With Anaplastic Glioma
For a more in-depth look at these data, please click here. Patients with anaplastic glioma without 1p/19q codeletion benefit from adjuvant chemotherapy, according to early results from a European phase III trial. The estimated 5-year survival rates were 56% with radiation therapy and...
ASCO 2016: Adding Capecitabine Chemotherapy to Gemcitabine Extends Survival After Pancreatic Cancer Surgery
For a more in-depth look at these data, as well as commentary, click here. A European phase III trial, one of the largest ever conducted in pancreatic cancer, showed that adding the oral drug capecitabine chemotherapy to gemcitabine prolongs survival without increased toxicity. Adjuvant...
ASCO 2016: Biosimilar Shows Comparable Efficacy and Safety to Trastuzumab in HER2-Positive Metastatic Breast Cancer
A biosimilar trastuzumab antibody (MYL-1401O) is comparable in efficacy and safety to trastuzumab (Herceptin) in women with HER2-positive advanced breast cancer, according to a randomized phase III study. The response rates were comparable among women who received trastuzumab and among...
ASCO 2016: Adding Intraperitoneal Chemotherapy to Intravenous Chemotherapy Slows Ovarian Cancer Progression
For some women with advanced ovarian cancer that was successfully treated surgically, delivering chemotherapy intraperitoneally as well as intravenously appears more effective than intravenous chemotherapy alone. For women who were initially treated with chemotherapy prior to surgery, the ...
Statement from FDA Commissioner Robert Califf, MD, on the Release of the Final Individual Patient Expanded Access Form
“Today, the U.S. Food and Drug Administration (FDA) finalized its efforts to streamline the process used by physicians to request expanded access, often called ‘compassionate use,’ to investigational drugs and biologics for their patients. As a physician, I understand the...
FDA Approves EGFR Mutation–Detecting Blood Test for Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the epidermal growth factor receptor (EGFR) inhibitor erlotinib (Tarceva). This is the first FDA-approved, blood-based genetic test that can detect EGFR gene mutations...
FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) today approved Netspot, the first kit for the preparation of Ga-68 dotatate injection, a radioactive diagnostic agent for positron-emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with...
Nearly 20% of Patients With Ovarian Cancer Do Not Undergo Surgery
Nearly 20% of women with ovarian cancer do not undergo surgery, despite it being a standard part of treatment recommendations, according to new research from the Perelman School of Medicine at the University of Pennsylvania. The findings, which suggest that women may live four times longer with...
Vulnerable Hospitals, Cancer Surgery Readmissions, and Penalizing Payment Programs
Readmission rates after complex cancer operations tend to be higher in hospitals that are considered to be vulnerable because they serve as safety nets in their communities or have a high number of Medicaid patients. Reasons for higher readmission rates are highly complex and involve socioeconomic...
ASCO Value Framework Update: A Statement by Julie M. Vose, MD, MBA, FASCO
ASCO today published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published by Schnipper et al in the Journal of Clinical Oncology, defines value as a combination of clinical benefit, side effects, and...
FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved fluciclovine F-18 (Axumin), a radioactive diagnostic agent for injection. Fluciclovine F-18 is indicated for positron-emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated...
Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States
A model developed to estimate the absolute risk of breast cancer suggests that a 30-year-old white woman in the United States has an 11.3% risk, on average, of developing invasive breast cancer by the age of 80, according to a new study published by Maas et al in JAMA Oncology. Breast cancer is a...
Women With New-Onset Atrial Fibrillation May Be at Increased Risk for Malignant Cancer
Among nearly 35,000 initially healthy women who were followed for about 20 years, those with new-onset atrial fibrillation had an increased risk of cancer, according to a study published by Conen et al in JAMA Cardiology. Atrial fibrillation, the most common cardiac arrhythmia, is associated with...
QOPI-Certified Practices Eligible to Receive Discount on Medical Malpractice Rates
ASCO and its wholly owned subsidiary, Quality Oncology Practice Initiative (QOPI®) Certification Program, LLC (QCP), announced May 25 that The Doctors Company, the nation's largest physician-owned medical malpractice insurer, will recognize QOPI® Certification in its rate structure....
DDW 2016: Rates of Colorectal Cancer Continue to Increase in Those Under 50
A new study shows the rate of colorectal cancer continues to increase in individuals under 50 years old, despite the fact that the overall rate of the disease has been declining in recent years. Following examination of more than 1 million colorectal cancer patient records over 10 years,...
DDW 2016: Low-Residue Diet Prior to Colonoscopy Shows Improved Tolerance and Bowel Preparation vs Clear Liquid Diet
A new study finds that patients who ate certain solid foods, considered “low residue,” were better prepared for their colonoscopies than individuals who followed the conventional liquid diet. Additionally, researchers saw that these patients who ate foods such as eggs, white bread,...
DDW 2016: Racial Disparities Found in Liver Cancer Survival Rates
Black patients diagnosed with hepatocellular carcinoma, the most common liver cancer, had a 33% increased risk of death compared to non-Hispanic whites. They also were far less likely to receive lifesaving liver transplants, according to a new study presented by Jones et al at Digestive Disease...
DDW 2016: Endoscopist’s Knowledge of Positive Cologuard Test Improves Colonoscopy Performance
An endoscopist's knowledge of a positive Cologuard test improves colonoscopy performance, according to a poster presentation by Johnson et al at Digestive Disease Week (DDW) 2016 (Abstract Su1044). Cologuard is an at-home, stool-DNA colorectal cancer screening test that has been approved by the...
New ASCO Cervical Cancer Guidelines Address Global Resource Disparities
On May 25, ASCO issued its first clinical practice guideline on invasive cervical cancer. This resource-stratified guideline is the first of its kind from ASCO, offering treatment recommendations tailored to resource availability. Access to cervical cancer care varies between regions of the...
Play-Based Procedural Preparation May Aid Children Undergoing Cranial Radiation Therapy
Play-based procedural preparation not only helps children cope with the stress and anxiety of radiation therapy, but can also help reduce the amount of sedation used and cut costs, according to a study from the Child Life Program at St. Jude Children’s Research Hospital. The study was...
Colleagues Tip Their Hats to Allen S. Lichter, MD, FASCO
After serving as ASCO’s CEO for 10 years, Allen S. Lichter, MD, FASCO, is stepping down. Dr. Lichter, who has been an ASCO member since 1980, has served the Society in numerous capacities. Along with his distinguished career at ASCO, Dr. Lichter is a nationally recognized radiation oncologist,...
Surgical Oncologist Suzanne L. Topalian, MD, Shines at the Forefront of Groundbreaking Research in Cancer Immunotherapy
Nationally recognized surgical oncologist and researcher Suzanne L. Topalian, MD, had an early interest in the arts as well as science and decided to major in English upon entering Wellesley College in Wellesley, Massachusetts. “I wanted to keep all my options open, so I also enrolled in a pre-med...
Noted Gastrointestinal Oncologist Leonard Saltz, MD, Tempers Optimism With Reality and Factors Cost Into the Equation of Value in Cancer Care
Leonard Saltz, MD, was born in New York, New York, and reared in Westchester County, in the suburbs of the City. Terrance Archer, his high-school biology teacher, whom Dr. Saltz described as a “force of nature,” a wonderful human being, and a major role model, influenced his nascent curiosity in...
In Memoriam
The ASCO Post remembers the following specialists in oncology who passed away in 2015–2016. Please write to editor@ASCOPost.com to recognize and pay tribute to others in a future issue. Mark R. Green, MD January 3, 1945–February 23, 2015 “Few people have impacted cancer clinical research in the...
Physician-Researcher Carolyn Jean Presley, MD, Envisions Enhancing Geriatric Oncology
Carolyn Jean Presley, MD, a Robert Wood Johnson Foundation clinical scholar in medical oncology at the Yale Cancer Center, was born in Duluth, Minnesota, which hugs the north shore of Lake Superior, making it one of the nation’s coldest cities during its long winters. She grew up the middle child...
